



CANADIAN  
NEUROLOGICAL  
SCIENCES  
FEDERATION  
FÉDÉRATION  
DES SCIENCES  
NEUROLOGIQUES  
DU CANADA

# You're invited to *The Future of ALS Diagnosis!*

We are excited to have you join us on  
**Wednesday, November 23, 2022** at 7:00–8:00pm EST.

Join the discussion with:

## **Agessandro Abrahao**

M.D., M.Sc.(Neuroscience), M.Sc.(Clinical Epidemiology)

Assistant Professor of Medicine (Neurology), University of Toronto

Staff Neurologist, Sunnybrook Health Sciences Centre

Associate Scientist, Sunnybrook Research Institute

Focused Ultrasound Investigator, Harquail Centre for Neuromodulation

## Program Overview

Healthcare professionals attending this event will explore challenges in diagnosing patients with ALS and discuss new developments in clinical research for expediting diagnosis. We will cover the new Gold Coast criteria, potential diagnostic biomarkers, and discuss the key role of early diagnosis in the initiation of novel therapeutics.

### By the end of this course participants will be able to:

- Identify key challenges in diagnosing patients with ALS, despite the new Gold Coast criteria
- Understand the role of novel biomarkers of upper and lower motor neuron dysfunction in expediting ALS diagnosis
- Recognize the importance of early diagnosis in the initiation of novel therapeutics

Register today!



You can also scan the QR code to register!

This event will take place over Zoom. However, you will not need to download Zoom to view if you select "Join from your browser."

This Webinar is an unaccredited group learning activity approved by the Canadian Neurological Sciences Federation. The program was developed by the Canadian Neurological Sciences Federation and the faculty and was planned to achieve scientific integrity, objectivity, and balance. Financial and in-kind support for this program was provided by Mitsubishi Tanabe Pharma Canada  
CNP-NON-CA-0128 10/22



Mitsubishi Tanabe Pharma Canada